Adenosine

  • Description and indication for use

    Adenosine is a purine nucleoside endogenous to all cells of the body.  It slows impulse generation in the sinoatrial node (negative chronotropic effect), impairs conduction through the atrioventricular node (negative dromotropic effect) and dilates the coronary arteries.  Adenosine activates specific receptors on the cell membrane. 

    Adenosine has a rapid onset and a short duration of action, effect usually lasting seconds to minutes.  It is used in the treatment of sustained paroxysmal supraventricular tachycardia (SVT).  Consultation with a Paediatric Cardiologist is always sought when Adenosine is being considered for use in the retrieval environment.

    Dose

    IV

    0.05 mg/kg (50 micrograms/kg).

    Dose may be increased by 0.05 mg/kg (50 micrograms/kg) every 2 minutes until tachycardia is terminated to a maximum dose of 0.25 mg/kg.1, 2

    Reconstitution/Dilution

    Ampoule = 6 mg in 2 mL (3 mg/mL).
    Store vial at room temperature, do not refrigerate (single use vial).

    For IV use

    Can be administered undiluted (3 mg/mL) or as a 1 mg/mL solution.2, 3

    To prepare 1 mg/mL solution:

    Withdraw 1 mL of 3 mg/mL solution and add to 2 mL of sodium chloride 0.9% in a 5 mL syringe = 3 mg in 3 mL = 1 mg/mL.

    Discard excess volume to obtain dose required or withdraw dose using another syringe.

    Route and method of administration

    IV

    Medical staff to be present when administered.

    Give by rapid IV push into a large peripheral vein over 1-2 seconds3.

    Infuse as close to IV site as possible.

    Flush line immediately with 2 - 3 mL of sodium chloride 0.9% (to push into central circulation).1-3

    Side effects:

    Adenosine has a very short duration of effect (half-life is less than 10 seconds) meaning that any adverse effects are generally rapidly reversible.4

    Flushing.

    Dyspnoea.

    Transient arrhythmias - may occur between termination of SVT and onset of normal sinus rhythm.

    Irritability.

    Bradycardia (minimal) may occur.

    Special precautions

    Contraindications

    Second or third degree AV block or sick sinus syndrome.

    Known sensitivity to Adenosine.

    Compatibilities

    Limited information.

    Compatible fluids:   sodium chloride 0.9%, glucose 5%, Hartman’s solution.3,5

    Otherwise administer alone or contact pharmacy for further information.

    Drug interactions

    Carbamazepine 

    Higher degrees of heart block may be produced in the presence of both agents.
    Dipyridamole Protects against degradation and can potentiate the clinical effects of Adenosine.   Lower doses of Adenosine may be adequate.
    Theophylline (and caffeine)      May reduce effectiveness of Adenosine due to antagonistic pharmacologic effects.
    Verapamil Possibility of prolonged bradycardia occurring if Aadenosine is used together with high doses of Verapamil.

    Nursing responsibilities

    Continuous cardiorespiratory monitor.

    Monitor blood pressure.

    References:

    1.    RCH Paediatric Pharmacopoeia, 13th ed. 2002.

    2.    RWH Neonatal Pharmacopoeia, 2nd ed. 2005.

    3.    RCH Paediatric Injectable Guidelines, 4th ed. 2011 ( http://ww2.rch.org.au/pharmacy/intranet/PIG.pdf- accessed 03/10/2013).

    4.    Australian Injectables Handbook, SHPA, 5th ed. 2011.

    5.    Lawrence Trissel, Handbook on Injectable Drugs, 17th ed. 2013.



Disclaimer:  This Drug information was designed for use by PIPER Neonatal. Whilst great care has been taken to check the information is accurate, it is possible that errors may have been missed. Furthermore, dosage schedules are continually being revised and new side effects recognised. For these reasons, the reader is strongly advised to consult the drug companies' printed information before administering any of the drugs recommended in this book.
Most drugs in this document are appropriate only for specialist use in hospitals.  A number of drugs should only be used in consultation with the appropriate Paediatric subspecialist. 

Note: The electronic version of this guideline is the version currently in use.  Any printed version cannot be assumed to be current. Printed copies of this document are valid for